Genetic and Transcriptomic Analyses of Ciprofloxacin-Tolerant Staphylococcus aureus Isolated by the Replica Plating Tolerance Isolation System (REPTIS)

Antimicrob Agents Chemother. 2019 Jan 29;63(2):e02019-18. doi: 10.1128/AAC.02019-18. Print 2019 Feb.

Abstract

We developed a simple, efficient, and cost-effective method, named the replica plating tolerance isolation system (REPTIS), to detect the antibiotic tolerance potential of a bacterial strain. This method can also be used to quantify the antibiotic-tolerant subpopulation in a susceptible population. Using REPTIS, we isolated ciprofloxacin (CPFX)-tolerant mutants (mutants R2, R3, R5, and R6) carrying a total of 12 mutations in 12 different genes from methicillin-sensitive Staphylococcus aureus (MSSA) strain FDA209P. Each mutant carried multiple mutations, while few strains shared the same mutation. The R2 strain carried a nonsense mutation in the stress-mediating gene, relA Additionally, two strains carried the same point mutation in the leuS gene, encoding leucyl-tRNA synthetase. Furthermore, RNA sequencing of the R strains showed a common upregulation of relA Overall, transcriptome analysis showed downregulation of genes related to translation; carbohydrate, fat, and energy metabolism; nucleotide synthesis; and upregulation of amino acid biosynthesis and transportation genes in R2, R3, and R6, similar to the findings observed for the FDA209P strain treated with mupirocin (MUP0.03). However, R5 showed a unique transcription pattern that differed from that of MUP0.03. REPTIS is a unique and convenient method for quantifying the level of tolerance of a clinical isolate. Genomic and transcriptomic analyses of R strains demonstrated that CPFX tolerance in these S. aureus mutants occurs via at least two distinct mechanisms, one of which is similar to that which occurs with mupirocin treatment.

Keywords: Staphylococcus aureus; ciprofloxacin tolerance; leuS; relA; tolerant mutant; transcriptome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Ciprofloxacin / pharmacology*
  • Drug Resistance, Bacterial / genetics*
  • GTP Pyrophosphokinase / genetics
  • Gene Expression Profiling / methods
  • Humans
  • Leucine-tRNA Ligase / genetics
  • Microbial Sensitivity Tests / methods*
  • Mupirocin / pharmacology
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / genetics*
  • Staphylococcus aureus / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Mupirocin
  • GTP Pyrophosphokinase
  • Leucine-tRNA Ligase